NextCure Total Stockholder Equity vs Long Term Debt Analysis

NXTC Stock

USD 1.29 0.01 0.77%

NextCure financial indicator trend analysis is infinitely more than just investigating NextCure recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NextCure is a good investment. Please check the relationship between NextCure Total Stockholder Equity and its Long Term Debt accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NextCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.

Total Stockholder Equity vs Long Term Debt

Total Stockholder Equity vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NextCure Total Stockholder Equity account and Long Term Debt. At this time, the significance of the direction appears to have almost identical trend.

The correlation between NextCure's Total Stockholder Equity and Long Term Debt is 0.93. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of NextCure, assuming nothing else is changed. The correlation between historical values of NextCure's Total Stockholder Equity and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of NextCure are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Total Stockholder Equity i.e., NextCure's Total Stockholder Equity and Long Term Debt go up and down completely randomly.

Correlation Coefficient

0.93

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Long Term Debt

Long-term debt is a debt that NextCure has held for over one year. Long-term debt appears on NextCure balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on NextCure balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Most indicators from NextCure's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NextCure current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NextCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.The current year's Sales General And Administrative To Revenue is expected to grow to 1.25, whereas Selling General Administrative is forecasted to decline to about 14.9 M.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	7.2M	4.1M	3.9M	3.7M
Total Operating Expenses	70.8M	75.9M	67.6M	56.6M

Reconciled Depreciation Total Operating Expenses

NextCure fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity
Total Assets		0.72	0.94	0.93	0.95	0.45	0.93	0.77	0.6	-0.27	-0.54	0.7	0.31	0.85	0.64	0.78	0.86	1.0	0.82	0.71	0.86	-0.25	0.83	0.26	0.79	0.63
Short Long Term Debt Total	0.72		0.89	0.59	0.81	0.02	0.85	0.83	0.17	0.13	-0.86	0.65	-0.07	0.84	0.85	0.53	0.84	0.7	0.95	0.91	0.84	-0.56	0.95	0.64	0.92	0.88
Other Current Liab	0.94	0.89		0.82	0.97	0.19	0.98	0.87	0.37	-0.03	-0.73	0.75	0.08	0.92	0.78	0.72	0.92	0.94	0.95	0.88	0.92	-0.5	0.96	0.47	0.91	0.82
Total Current Liabilities	0.93	0.59	0.82		0.8	0.66	0.79	0.67	0.79	-0.47	-0.48	0.69	0.52	0.79	0.64	0.78	0.78	0.93	0.7	0.55	0.78	0.0	0.71	0.32	0.58	0.46
Total Stockholder Equity	0.95	0.81	0.97	0.8		0.17	0.99	0.79	0.38	0.05	-0.59	0.66	0.0	0.86	0.66	0.77	0.93	0.94	0.89	0.8	0.93	-0.55	0.9	0.3	0.86	0.72
Other Liab	0.45	0.02	0.19	0.66	0.17		0.15	0.02	0.95	-0.86	0.1	0.15	0.87	0.12	0.07	0.37	0.2	0.46	0.05	-0.12	0.2	0.68	0.07	-0.17	0.02	-0.18
Net Tangible Assets	0.93	0.85	0.98	0.79	0.99	0.15		0.8	0.36	0.06	-0.66	0.66	-0.01	0.87	0.73	0.73	0.95	0.92	0.94	0.84	0.95	-0.57	0.95	0.38	0.88	0.77
Property Plant And Equipment Net	0.77	0.83	0.87	0.67	0.79	0.02	0.8		0.11	-0.08	-0.82	0.95	0.14	0.97	0.87	0.6	0.67	0.75	0.87	0.94	0.67	-0.41	0.88	0.66	0.81	0.92
Current Deferred Revenue	0.6	0.17	0.37	0.79	0.38	0.95	0.36	0.11		-0.69	0.0	0.2	0.71	0.27	0.19	0.55	0.45	0.62	0.23	0.0	0.45	0.44	0.24	-0.09	0.14	-0.09
Net Debt	-0.27	0.13	-0.03	-0.47	0.05	-0.86	0.06	-0.08	-0.69		-0.1	-0.29	-1.0	-0.09	-0.07	-0.17	0.12	-0.28	0.07	0.09	0.12	-0.85	0.07	0.14	0.08	0.09
Retained Earnings	-0.54	-0.86	-0.73	-0.48	-0.59	0.1	-0.66	-0.82	0.0	-0.1		-0.69	0.04	-0.78	-0.9	-0.23	-0.62	-0.52	-0.85	-0.88	-0.62	0.45	-0.83	-0.9	-0.76	-0.87
Accounts Payable	0.7	0.65	0.75	0.69	0.66	0.15	0.66	0.95	0.2	-0.29	-0.69		0.35	0.93	0.83	0.64	0.52	0.69	0.73	0.8	0.52	-0.18	0.74	0.61	0.61	0.79
Cash	0.31	-0.07	0.08	0.52	0.0	0.87	-0.01	0.14	0.71	-1.0	0.04	0.35		0.15	0.14	0.21	-0.07	0.32	-0.01	-0.04	-0.07	0.82	-0.01	-0.07	-0.04	-0.04
Non Current Assets Total	0.85	0.84	0.92	0.79	0.86	0.12	0.87	0.97	0.27	-0.09	-0.78	0.93	0.15		0.89	0.74	0.79	0.84	0.9	0.89	0.79	-0.43	0.91	0.64	0.78	0.85
Non Currrent Assets Other	0.64	0.85	0.78	0.64	0.66	0.07	0.73	0.87	0.19	-0.07	-0.9	0.83	0.14	0.89		0.51	0.71	0.62	0.9	0.88	0.71	-0.36	0.89	0.82	0.7	0.87
Other Assets	0.78	0.53	0.72	0.78	0.77	0.37	0.73	0.6	0.55	-0.17	-0.23	0.64	0.21	0.74	0.51		0.75	0.78	0.6	0.46	0.75	-0.26	0.63	0.13	0.46	0.39
Long Term Debt	0.86	0.84	0.92	0.78	0.93	0.2	0.95	0.67	0.45	0.12	-0.62	0.52	-0.07	0.79	0.71	0.75		0.85	0.9	0.72	1.0	-0.56	0.9	0.41	0.78	0.63
Cash And Short Term Investments	1.0	0.7	0.94	0.93	0.94	0.46	0.92	0.75	0.62	-0.28	-0.52	0.69	0.32	0.84	0.62	0.78	0.85		0.81	0.7	0.85	-0.24	0.82	0.24	0.78	0.61
Common Stock Total Equity	0.82	0.95	0.95	0.7	0.89	0.05	0.94	0.87	0.23	0.07	-0.85	0.73	-0.01	0.9	0.9	0.6	0.9	0.81		0.95	0.9	-0.56	1.0	0.61	0.91	0.91
Common Stock Shares Outstanding	0.71	0.91	0.88	0.55	0.8	-0.12	0.84	0.94	0.0	0.09	-0.88	0.8	-0.04	0.89	0.88	0.46	0.72	0.7	0.95		0.72	-0.56	0.94	0.64	0.92	0.99
Long Term Debt Total	0.86	0.84	0.92	0.78	0.93	0.2	0.95	0.67	0.45	0.12	-0.62	0.52	-0.07	0.79	0.71	0.75	1.0	0.85	0.9	0.72		-0.56	0.9	0.41	0.78	0.63
Non Current Liabilities Total	-0.25	-0.56	-0.5	0.0	-0.55	0.68	-0.57	-0.41	0.44	-0.85	0.45	-0.18	0.82	-0.43	-0.36	-0.26	-0.56	-0.24	-0.56	-0.56	-0.56		-0.56	-0.35	-0.54	-0.53
Capital Surpluse	0.83	0.95	0.96	0.71	0.9	0.07	0.95	0.88	0.24	0.07	-0.83	0.74	-0.01	0.91	0.89	0.63	0.9	0.82	1.0	0.94	0.9	-0.56		0.59	0.92	0.9
Capital Lease Obligations	0.26	0.64	0.47	0.32	0.3	-0.17	0.38	0.66	-0.09	0.14	-0.9	0.61	-0.07	0.64	0.82	0.13	0.41	0.24	0.61	0.64	0.41	-0.35	0.59		0.42	0.65
Other Current Assets	0.79	0.92	0.91	0.58	0.86	0.02	0.88	0.81	0.14	0.08	-0.76	0.61	-0.04	0.78	0.7	0.46	0.78	0.78	0.91	0.92	0.78	-0.54	0.92	0.42		0.88
Other Stockholder Equity	0.63	0.88	0.82	0.46	0.72	-0.18	0.77	0.92	-0.09	0.09	-0.87	0.79	-0.04	0.85	0.87	0.39	0.63	0.61	0.91	0.99	0.63	-0.53	0.9	0.65	0.88

Click cells to compare fundamentals

NextCure Account Relationship Matchups

NextCure fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	356.2M	306.6M	242.4M	184.2M	128.0M	217.6M
Short Long Term Debt Total	587K	5.1M	3.5M	7.1M	6.6M	4.4M
Other Current Liab	5.0M	4.8M	4.7M	4.3M	3.9M	4.2M
Total Current Liabilities	15.0M	10.3M	6.6M	9.1M	6.9M	9.6M
Total Stockholder Equity	321.5M	293.7M	233.4M	167.5M	114.4M	166.4M
Other Liab	16.3M	792K	2.4M	899K	809.1K	768.6K
Net Tangible Assets	321.5M	293.7M	233.4M	167.5M	192.7M	173.2M
Property Plant And Equipment Net	12.1M	15.8M	14.0M	16.9M	13.4M	14.7M
Net Debt	(29.0M)	(29.3M)	(12.3M)	(19.5M)	(6.5M)	(6.8M)
Retained Earnings	(81.0M)	(117.6M)	(187.0M)	(261.8M)	(324.5M)	(308.3M)
Accounts Payable	1.9M	3.9M	1.9M	4.3M	2.3M	2.8M
Cash	34.1M	32.8M	12.3M	26.6M	13.1M	12.4M
Non Current Assets Total	16.2M	18.7M	14.6M	20.2M	15.3M	16.8M
Non Currrent Assets Other	750K	1.1M	577K	1.7M	1.9M	1.0M
Other Assets	436K	4.1M	2.9M	577K	3.3M	0.0
Cash And Short Term Investments	334.6M	283.4M	219.6M	159.9M	108.3M	196.3M
Common Stock Shares Outstanding	15.7M	27.5M	27.6M	27.7M	27.8M	23.0M
Short Term Investments	300.5M	250.7M	207.3M	133.3M	95.2M	155.1M
Liabilities And Stockholders Equity	356.2M	306.6M	242.4M	184.2M	128.0M	217.6M
Non Current Liabilities Total	19.6M	2.6M	2.4M	7.5M	6.7M	6.4M
Capital Surpluse	402.5M	410.6M	421.0M	430.8M	495.4M	305.3M
Capital Lease Obligations	127K	135K	0.0	7.1M	6.6M	6.9M
Other Current Assets	3.7M	4.5M	8.2M	4.1M	4.4M	4.0M
Other Stockholder Equity	46.4M	410.6M	421.0M	430.8M	439.1M	275.2M
Total Liab	34.7M	12.9M	9M	16.6M	13.6M	12.9M
Net Invested Capital	326.5M	297.2M	233.4M	167.5M	114.4M	168.0M
Property Plant And Equipment Gross	12.1M	15.8M	26.7M	33.5M	33.7M	22.5M
Total Current Assets	340.0M	288.0M	227.8M	164.0M	112.7M	200.8M
Accumulated Other Comprehensive Income	(38K)	779K	(663K)	(1.5M)	(222K)	(233.1K)
Net Working Capital	325.0M	277.7M	221.2M	154.9M	105.8M	191.1M
Short Term Debt	514K	1.8M	1.7M	518K	656K	1.0M
Property Plant Equipment	12.1M	15.8M	14.0M	11.9M	13.7M	13.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GOOG	Alphabet Inc Class C
CRM	Salesforce

When determining whether NextCure offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NextCure's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nextcure Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nextcure Stock:

How To Invest In NextCure

Details

Is NextCure Stock a good investment?

Details

What is NextCure's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NextCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.

You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NextCure. If investors know NextCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NextCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.08)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.31)

Return On Equity

(0.55)

The market value of NextCure is measured differently than its book value, which is the value of NextCure that is recorded on the company's balance sheet. Investors also form their own opinion of NextCure's value that differs from its market value or its book value, called intrinsic value, which is NextCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NextCure's market value can be influenced by many factors that don't directly affect NextCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between NextCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if NextCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NextCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NextCure Total Stockholder Equity vs Long Term Debt Analysis

Total Stockholder Equity vs Long Term Debt

Total Stockholder Equity vs Long Term Debt Correlation Analysis

Correlation Coefficient

Total Stockholder Equity

Long Term Debt

NextCure fundamental ratios Correlations

NextCure Account Relationship Matchups

High Positive Relationship

High Negative Relationship

NextCure fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Long Term Debt Total	+ 1.0	Long Term Debt
Capital Surpluse	+ 1.0	Common Stock Total Equity
Net Tangible Assets	+ 0.99	Total Stockholder Equity
Other Stockholder Equity	+ 0.99	Common Stock Shares Outstanding
Net Tangible Assets	+ 0.98	Other Current Liab

Cash	- 1.0	Net Debt
Capital Lease Obligations	- 0.9	Retained Earnings
Non Currrent Assets Other	- 0.9	Retained Earnings
Common Stock Shares Outstanding	- 0.88	Retained Earnings
Other Stockholder Equity	- 0.87	Retained Earnings
Net Debt	- 0.86	Other Liab